The stock of Accuray (NASDAQ:ARAY) registered an increase of 3.13% in short interest. ARAY’s total short interest was 11.27 million shares in March as published by FINRA. Its up 3.13% from 10.93M shares, reported previously. With 1.19 million shares average volume, it will take short sellers 10 days to cover their ARAY’s short positions. The short interest to Accuray’s float is 15.18%. The stock is down 0.55% or $0.03 after the news, hitting $5.4 per share. About 25,676 shares traded hands. Accuray Incorporated (NASDAQ:ARAY) has declined 14.22% since August 3, 2015 and is downtrending. It has underperformed by 8.56% the S&P500.
Accuray Incorporated is a radiation oncology company. The company has a market cap of $434.15 million. The Firm develops, makes, sells and supports treatment solutions. It currently has negative earnings. The Company’s suite of products includes the CyberKnife Systems and the TomoTherapy Systems.
The institutional sentiment decreased to 1.14 in Q3 2015. Its down 0.14, from 1.28 in 2015Q2. The ratio is negative, as 19 funds sold all Accuray Incorporated shares owned while 37 reduced positions. 16 funds bought stakes while 48 increased positions. They now own 84.65 million shares or 10.05% more from 76.92 million shares in 2015Q2.
Oracle Investment Management Inc holds 2.95% of its portfolio in Accuray Incorporated for 2.88 million shares. Ardsley Advisory Partners owns 1.77 million shares or 2.14% of their US portfolio. Moreover, Pura Vida Investments Llc has 2.03% invested in the company for 713,700 shares. The Connecticut-based Lapides Asset Management Llc has invested 1.81% in the stock. Partner Fund Management L.P., a California-based fund reported 5.77 million shares.
Out of 8 analysts covering Accuray (NASDAQ:ARAY), 6 rate it “Buy”, 1 “Sell”, while 3 “Hold”. This means 60% are positive. Accuray was the topic in 6 analyst reports since August 5, 2015 according to StockzIntelligence Inc. RBC Capital Markets maintained the stock on January 29 with “Sector Perform” rating.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.